Search

Your search keyword '"Moynihan C"' showing total 328 results
Start Over Author "Moynihan C"
328 results on '"Moynihan C"'

6. DIII-D research advancing the physics basis for optimizing the tokamak approach to fusion energy

Author

Fenstermacher, M. E., primary, Abbate, J., additional, Abe, S., additional, Abrams, T., additional, Adams, M., additional, Adamson, B., additional, Aiba, N., additional, Akiyama, T., additional, Aleynikov, P., additional, Allen, E., additional, Allen, S., additional, Anand, H., additional, Anderson, J., additional, Andrew, Y., additional, Andrews, T., additional, Appelt, D., additional, Arbon, R., additional, Ashikawa, N., additional, Ashourvan, A., additional, Aslin, M., additional, Asnis, Y., additional, Austin, M., additional, Ayala, D., additional, Bak, J., additional, Bandyopadhyay, I., additional, Banerjee, S., additional, Barada, K., additional, Bardoczi, L., additional, Barr, J., additional, Bass, E., additional, Battaglia, D., additional, Battey, A., additional, Baumgartner, W., additional, Baylor, L., additional, Beckers, J., additional, Beidler, M., additional, Belli, E., additional, Berkery, J., additional, Bernard, T., additional, Bertelli, N., additional, Beurskens, M., additional, Bielajew, R., additional, Bilgili, S., additional, Biswas, B., additional, Blondel, S., additional, Boedo, J., additional, Bogatu, I., additional, Boivin, R., additional, Bolzonella, T., additional, Bongard, M., additional, Bonnin, X., additional, Bonoli, P., additional, Bonotto, M., additional, Bortolon, A., additional, Bose, S., additional, Bosviel, N., additional, Bouwmans, S., additional, Boyer, M., additional, Boyes, W., additional, Bradley, L., additional, Brambila, R., additional, Brennan, D., additional, Bringuier, S., additional, Brodsky, L., additional, Brookman, M., additional, Brooks, J., additional, Brower, D., additional, Brown, G., additional, Brown, W., additional, Burke, M., additional, Burrell, K., additional, Butler, K., additional, Buttery, R., additional, Bykov, I., additional, Byrne, P., additional, Cacheris, A., additional, Callahan, K., additional, Callen, J., additional, Campbell, G., additional, Candy, J., additional, Canik, J., additional, Cano-Megias, P., additional, Cao, N., additional, Carayannopoulos, L., additional, Carlstrom, T., additional, Carrig, W., additional, Carter, T., additional, Cary, W., additional, Casali, L., additional, Cengher, M., additional, Cespedes Paz, G., additional, Chaban, R., additional, Chan, V., additional, Chapman, B., additional, Char, I., additional, Chattopadhyay, A., additional, Chen, R., additional, Chen, J., additional, Chen, X., additional, Chen, M., additional, Chen, Z., additional, Choi, M., additional, Choi, W., additional, Choi, G., additional, Chousal, L., additional, Chrobak, C., additional, Chrystal, C., additional, Chung, Y., additional, Churchill, R., additional, Cianciosa, M., additional, Clark, J., additional, Clement, M., additional, Coda, S., additional, Cole, A., additional, Collins, C., additional, Conlin, W., additional, Cooper, A., additional, Cordell, J., additional, Coriton, B., additional, Cote, T., additional, Cothran, J., additional, Creely, A., additional, Crocker, N., additional, Crowe, C., additional, Crowley, B., additional, Crowley, T., additional, Cruz-Zabala, D., additional, Cummings, D., additional, Curie, M., additional, Curreli, D., additional, Dal Molin, A., additional, Dannels, B., additional, Dautt-Silva, A., additional, Davda, K., additional, De Tommasi, G., additional, De Vries, P., additional, Degrandchamp, G., additional, Degrassie, J., additional, Demers, D., additional, Denk, S., additional, Depasquale, S., additional, Deshazer, E., additional, Diallo, A., additional, Diem, S., additional, Dimits, A., additional, Ding, R., additional, Ding, S., additional, Ding, W., additional, Do, T., additional, Doane, J., additional, Dong, G., additional, Donovan, D., additional, Drake, J., additional, Drews, W., additional, Drobny, J., additional, Du, X., additional, Du, H., additional, Duarte, V., additional, Dudt, D., additional, Dunn, C., additional, Duran, J., additional, Dvorak, A., additional, Effenberg, F., additional, Eidietis, N., additional, Elder, D., additional, Eldon, D., additional, Ellis, R., additional, Elwasif, W., additional, Ennis, D., additional, Erickson, K., additional, Ernst, D., additional, Fasciana, M., additional, Fedorov, D., additional, Feibush, E., additional, Ferraro, N., additional, Ferreira, J., additional, Ferron, J., additional, Fimognari, P., additional, Finkenthal, D., additional, Fitzpatrick, R., additional, Fox, P., additional, Fox, W., additional, Frassinetti, L., additional, Frerichs, H., additional, Frye, H., additional, Fu, Y., additional, Gage, K., additional, Galdon Quiroga, J., additional, Gallo, A., additional, Gao, Q., additional, Garcia, A., additional, Garcia Munoz, M., additional, Garnier, D., additional, Garofalo, A., additional, Gattuso, A., additional, Geng, D., additional, Gentle, K., additional, Ghosh, D., additional, Giacomelli, L., additional, Gibson, S., additional, Gilson, E., additional, Giroud, C., additional, Glass, F., additional, Glasser, A., additional, Glibert, D., additional, Gohil, P., additional, Gomez, R., additional, Gomez, S., additional, Gong, X., additional, Gonzales, E., additional, Goodman, A., additional, Gorelov, Y., additional, Graber, V., additional, Granetz, R., additional, Gray, T., additional, Green, D., additional, Greenfield, C., additional, Greenwald, M., additional, Grierson, B., additional, Groebner, R., additional, Grosnickle, W., additional, Groth, M., additional, Grunloh, H., additional, Gu, S., additional, Guo, W., additional, Guo, H., additional, Gupta, P., additional, Guterl, J., additional, Guttenfelder, W., additional, Guzman, T., additional, Haar, S., additional, Hager, R., additional, Hahn, S., additional, Halfmoon, M., additional, Hall, T., additional, Hallatschek, K., additional, Halpern, F., additional, Hammett, G., additional, Han, H., additional, Hansen, E., additional, Hansen, C., additional, Hansink, M., additional, Hanson, J., additional, Hanson, M., additional, Hao, G., additional, Harris, A., additional, Harvey, R., additional, Haskey, S., additional, Hassan, E., additional, Hassanein, A., additional, Hatch, D., additional, Hawryluk, R., additional, Hayashi, W., additional, Heidbrink, W., additional, Herfindal, J., additional, Hicok, J., additional, Hill, D., additional, Hinson, E., additional, Holcomb, C., additional, Holland, L., additional, Holland, C., additional, Hollmann, E., additional, Hollocombe, J., additional, Holm, A., additional, Holmes, I., additional, Holtrop, K., additional, Honda, M., additional, Hong, R., additional, Hood, R., additional, Horton, A., additional, Horvath, L., additional, Hosokawa, M., additional, Houshmandyar, S., additional, Howard, N., additional, Howell, E., additional, Hoyt, D., additional, Hu, W., additional, Hu, Y., additional, Hu, Q., additional, Huang, J., additional, Huang, Y., additional, Hughes, J., additional, Human, T., additional, Humphreys, D., additional, Huynh, P., additional, Hyatt, A., additional, Ibanez, C., additional, Ibarra, L., additional, Icasas, R., additional, Ida, K., additional, Igochine, V., additional, In, Y., additional, Inoue, S., additional, Isayama, A., additional, Izacard, O., additional, Izzo, V., additional, Jackson, A., additional, Jacobsen, G., additional, Jaervinen, A., additional, Jalalvand, A., additional, Janhunen, J., additional, Jardin, S., additional, Jarleblad, H., additional, Jeon, Y., additional, Ji, H., additional, Jian, X., additional, Joffrin, E., additional, Johansen, A., additional, Johnson, C., additional, Johnson, T., additional, Jones, C., additional, Joseph, I., additional, Jubas, D., additional, Junge, B., additional, Kalb, W., additional, Kalling, R., additional, Kamath, C., additional, Kang, J., additional, Kaplan, D., additional, Kaptanoglu, A., additional, Kasdorf, S., additional, Kates-Harbeck, J., additional, Kazantzidis, P., additional, Kellman, A., additional, Kellman, D., additional, Kessel, C., additional, Khumthong, K., additional, Kim, E., additional, Kim, H., additional, Kim, J., additional, Kim, S., additional, Kim, K., additional, Kim, C., additional, Kimura, W., additional, King, M., additional, King, J., additional, Kinsey, J., additional, Kirk, A., additional, Kiyan, B., additional, Kleiner, A., additional, Klevarova, V., additional, Knapp, R., additional, Knolker, M., additional, Ko, W., additional, Kobayashi, T., additional, Koch, E., additional, Kochan, M., additional, Koel, B., additional, Koepke, M., additional, Kohn, A., additional, Kolasinski, R., additional, Kolemen, E., additional, Kostadinova, E., additional, Kostuk, M., additional, Kramer, G., additional, Kriete, D., additional, Kripner, L., additional, Kubota, S., additional, Kulchar, J., additional, Kwon, K., additional, La Haye, R., additional, Laggner, F., additional, Lan, H., additional, Lantsov, R., additional, Lao, L., additional, Lasa Esquisabel, A., additional, Lasnier, C., additional, Lau, C., additional, Leard, B., additional, Lee, J., additional, Lee, R., additional, Lee, M., additional, Lee, Y., additional, Lee, C., additional, Lee, S., additional, Lehnen, M., additional, Leonard, A., additional, Leppink, E., additional, Lesher, M., additional, Lestz, J., additional, Leuer, J., additional, Leuthold, N., additional, Li, X., additional, Li, K., additional, Li, E., additional, Li, G., additional, Li, L., additional, Li, Z., additional, Li, J., additional, Li, Y., additional, Lin, Z., additional, Lin, D., additional, Liu, X., additional, Liu, J., additional, Liu, Y., additional, Liu, T., additional, Liu, C., additional, Liu, Z., additional, Liu, D., additional, Liu, A., additional, Loarte-Prieto, A., additional, Lodestro, L., additional, Logan, N., additional, Lohr, J., additional, Lombardo, B., additional, Lore, J., additional, Luan, Q., additional, Luce, T., additional, Luda Di Cortemiglia, T., additional, Luhmann, N., additional, Lunsford, R., additional, Luo, Z., additional, Lvovskiy, A., additional, Lyons, B., additional, Ma, X., additional, Madruga, M., additional, Madsen, B., additional, Maggi, C., additional, Maheshwari, K., additional, Mail, A., additional, Mailloux, J., additional, Maingi, R., additional, Major, M., additional, Makowski, M., additional, Manchanda, R., additional, Marini, C., additional, Marinoni, A., additional, Maris, A., additional, Markovic, T., additional, Marrelli, L., additional, Martin, E., additional, Mateja, J., additional, Matsunaga, G., additional, Maurizio, R., additional, Mauzey, P., additional, Mauzey, D., additional, Mcardle, G., additional, Mcclenaghan, J., additional, Mccollam, K., additional, Mcdevitt, C., additional, Mckay, K., additional, Mckee, G., additional, Mclean, A., additional, Mehta, V., additional, Meier, E., additional, Menard, J., additional, Meneghini, O., additional, Merlo, G., additional, Messer, S., additional, Meyer, W., additional, Michael, C., additional, Michoski, C., additional, Milne, P., additional, Minet, G., additional, Misleh, A., additional, Mitrishkin, Y., additional, Moeller, C., additional, Montes, K., additional, Morales, M., additional, Mordijck, S., additional, Moreau, D., additional, Morosohk, S., additional, Morris, P., additional, Morton, L., additional, Moser, A., additional, Moyer, R., additional, Moynihan, C., additional, Mrazkova, T., additional, Mueller, D., additional, Munaretto, S., additional, Munoz Burgos, J., additional, Murphy, C., additional, Murphy, K., additional, Muscatello, C., additional, Myers, C., additional, Nagy, A., additional, Nandipati, G., additional, Navarro, M., additional, Nave, F., additional, Navratil, G., additional, Nazikian, R., additional, Neff, A., additional, Neilson, G., additional, Neiser, T., additional, Neiswanger, W., additional, Nelson, D., additional, Nelson, A., additional, Nespoli, F., additional, Nguyen, R., additional, Nguyen, L., additional, Nguyen, X., additional, Nichols, J., additional, Nocente, M., additional, Nogami, S., additional, Noraky, S., additional, Norausky, N., additional, Nornberg, M., additional, Nygren, R., additional, Odstrcil, T., additional, Ogas, D., additional, Ogorman, T., additional, Ohdachi, S., additional, Ohtani, Y., additional, Okabayashi, M., additional, Okamoto, M., additional, Olavson, L., additional, Olofsson, E., additional, Omullane, M., additional, Oneill, R., additional, Orlov, D., additional, Orvis, W., additional, Osborne, T., additional, Pace, D., additional, Paganini Canal, G., additional, Pajares Martinez, A., additional, Palacios, L., additional, Pan, C., additional, Pan, Q., additional, Pandit, R., additional, Pandya, M., additional, Pankin, A., additional, Park, Y., additional, Park, J., additional, Parker, S., additional, Parks, P., additional, Parsons, M., additional, Patel, B., additional, Pawley, C., additional, Paz-Soldan, C., additional, Peebles, W., additional, Pelton, S., additional, Perillo, R., additional, Petty, C., additional, Peysson, Y., additional, Pierce, D., additional, Pigarov, A., additional, Pigatto, L., additional, Piglowski, D., additional, Pinches, S., additional, Pinsker, R., additional, Piovesan, P., additional, Piper, N., additional, Pironti, A., additional, Pitts, R., additional, Pizzo, J., additional, Plank, U., additional, Podesta, M., additional, Poli, E., additional, Poli, F., additional, Ponce, D., additional, Popovic, Z., additional, Porkolab, M., additional, Porter, G., additional, Powers, C., additional, Powers, S., additional, Prater, R., additional, Pratt, Q., additional, Pusztai, I., additional, Qian, J., additional, Qin, X., additional, Ra, O., additional, Rafiq, T., additional, Raines, T., additional, Raman, R., additional, Rauch, J., additional, Raymond, A., additional, Rea, C., additional, Reich, M., additional, Reiman, A., additional, Reinhold, S., additional, Reinke, M., additional, Reksoatmodjo, R., additional, Ren, Q., additional, Ren, Y., additional, Ren, J., additional, Rensink, M., additional, Renteria, J., additional, Rhodes, T., additional, Rice, J., additional, Roberts, R., additional, Robinson, J., additional, Rodriguez Fernandez, P., additional, Rognlien, T., additional, Rosenthal, A., additional, Rosiello, S., additional, Rost, J., additional, Roveto, J., additional, Rowan, W., additional, Rozenblat, R., additional, Ruane, J., additional, Rudakov, D., additional, Ruiz Ruiz, J., additional, Rupani, R., additional, Saarelma, S., additional, Sabbagh, S., additional, Sachdev, J., additional, Saenz, J., additional, Saib, S., additional, Salewski, M., additional, Salmi, A., additional, Sammuli, B., additional, Samuell, C., additional, Sandorfi, A., additional, Sang, C., additional, Sarff, J., additional, Sauter, O., additional, Schaubel, K., additional, Schmitz, L., additional, Schmitz, O., additional, Schneider, J., additional, Schroeder, P., additional, Schultz, K., additional, Schuster, E., additional, Schwartz, J., additional, Sciortino, F., additional, Scotti, F., additional, Scoville, J., additional, Seltzman, A., additional, Seol, S., additional, Sfiligoi, I., additional, Shafer, M., additional, Sharapov, S., additional, Shen, H., additional, Sheng, Z., additional, Shepard, T., additional, Shi, S., additional, Shibata, Y., additional, Shin, G., additional, Shiraki, D., additional, Shousha, R., additional, Si, H., additional, Simmerling, P., additional, Sinclair, G., additional, Sinha, J., additional, Sinha, P., additional, Sips, G., additional, Sizyuk, T., additional, Skinner, C., additional, Sladkomedova, A., additional, Slendebroek, T., additional, Slief, J., additional, Smirnov, R., additional, Smith, J., additional, Smith, S., additional, Smith, D., additional, Snipes, J., additional, Snoep, G., additional, Snyder, A., additional, Snyder, P., additional, Solano, E., additional, Solomon, W., additional, Song, J., additional, Sontag, A., additional, Soukhanovskii, V., additional, Spendlove, J., additional, Spong, D., additional, Squire, J., additional, Srinivasan, C., additional, Stacey, W., additional, Staebler, G., additional, Stagner, L., additional, Stange, T., additional, Stangeby, P., additional, Stefan, R., additional, Stemprok, R., additional, Stephan, D., additional, Stillerman, J., additional, Stoltzfus-Dueck, T., additional, Stonecipher, W., additional, Storment, S., additional, Strait, E., additional, Su, D., additional, Sugiyama, L., additional, Sun, Y., additional, Sun, P., additional, Sun, Z., additional, Sun, A., additional, Sundstrom, D., additional, Sung, C., additional, Sungcoco, J., additional, Suttrop, W., additional, Suzuki, Y., additional, Suzuki, T., additional, Svyatkovskiy, A., additional, Swee, C., additional, Sweeney, R., additional, Sweetnam, C., additional, Szepesi, G., additional, Takechi, M., additional, Tala, T., additional, Tanaka, K., additional, Tang, X., additional, Tang, S., additional, Tao, Y., additional, Tao, R., additional, Taussig, D., additional, Taylor, T., additional, Teixeira, K., additional, Teo, K., additional, Theodorsen, A., additional, Thomas, D., additional, Thome, K., additional, Thorman, A., additional, Thornton, A., additional, Ti, A., additional, Tillack, M., additional, Timchenko, N., additional, Tinguely, R., additional, Tompkins, R., additional, Tooker, J., additional, Torrezan De Sousa, A., additional, Trevisan, G., additional, Tripathi, S., additional, Trujillo Ochoa, A., additional, Truong, D., additional, Tsui, C., additional, Turco, F., additional, Turnbull, A., additional, Umansky, M., additional, Unterberg, E., additional, Vaezi, P., additional, Vail, P., additional, Valdez, J., additional, Valkis, W., additional, Van Compernolle, B., additional, Van Galen, J., additional, Van Kampen, R., additional, Van Zeeland, M., additional, Verdoolaege, G., additional, Vianello, N., additional, Victor, B., additional, Viezzer, E., additional, Vincena, S., additional, Wade, M., additional, Waelbroeck, F., additional, Wai, J., additional, Wakatsuki, T., additional, Walker, M., additional, Wallace, G., additional, Waltz, R., additional, Wampler, W., additional, Wang, L., additional, Wang, H., additional, Wang, Y., additional, Wang, Z., additional, Wang, G., additional, Ward, S., additional, Watkins, M., additional, Watkins, J., additional, Wehner, W., additional, Wei, Y., additional, Weiland, M., additional, Weisberg, D., additional, Welander, A., additional, White, A., additional, White, R., additional, Wiesen, S., additional, Wilcox, R., additional, Wilks, T., additional, Willensdorfer, M., additional, Wilson, H., additional, Wingen, A., additional, Wolde, M., additional, Wolff, M., additional, Woller, K., additional, Wolz, A., additional, Wong, H., additional, Woodruff, S., additional, Wu, M., additional, Wu, Y., additional, Wukitch, S., additional, Wurden, G., additional, Xiao, W., additional, Xie, R., additional, Xing, Z., additional, Xu, X., additional, Xu, C., additional, Xu, G., additional, Yan, Z., additional, Yang, X., additional, Yang, S., additional, Yokoyama, T., additional, Yoneda, R., additional, Yoshida, M., additional, You, K., additional, Younkin, T., additional, Yu, J., additional, Yu, M., additional, Yu, G., additional, Yuan, Q., additional, Zaidenberg, L., additional, Zakharov, L., additional, Zamengo, A., additional, Zamperini, S., additional, Zarnstorff, M., additional, Zeger, E., additional, Zeller, K., additional, Zeng, L., additional, Zerbini, M., additional, Zhang, L., additional, Zhang, X., additional, Zhang, R., additional, Zhang, B., additional, Zhang, J., additional, Zhao, L., additional, Zhao, B., additional, Zheng, Y., additional, Zheng, L., additional, Zhu, B., additional, Zhu, J., additional, Zhu, Y., additional, Zsutty, M., additional, and Zuin, M., additional

Published
2022
Full Text
View/download PDF

13. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study

Author

Mitra, Anita V., Bancroft, Elizabeth K., Barbachano, Yolanda, Page, Elizabeth C., Foster, C. S., Jameson, C., Mitchell, G., Lindeman, G. J., Stapleton, A., Suthers, G., Evans, D. G., Cruger, D., Blanco, I., Mercer, C., Kirk, J., Maehle, L., Hodgson, S., Walker, L., Izatt, L., Douglas, F., Tucker, K., Dorkins, H., Clowes, V., Male, A., Donaldson, A., Brewer, C., Doherty, R., Bulman, B., Osther, P. J., Salinas, M., Eccles, D., Axcrona, K., Jobson, I., Newcombe, B., Cybulski, C., Rubinstein, W. S., Buys, S., Townshend, S., Friedman, E., Domchek, S., Ramon y Cajal, T., Spigelman, A., Teo, S. H., Nicolai, N., Aaronson, N., Ardern-Jones, A., Bangma, C., Dearnaley, D., Eyfjord, J., Falconer, A., Grönberg, H., Hamdy, F., Johannsson, O., Khoo, V., Kote-Jarai, Z., Lilja, H., Lubinski, J., Melia, J., Moynihan, C., Peock, S., Rennert, G., Schröder, F., Sibley, P., Suri, M., Wilson, P., Bignon, Y. J., Strom, S., Tischkowitz, M., Liljegren, A., Ilencikova, D., Abele, A., Kyriacou, K., van Asperen, C., Kiemeney, L., Easton, D. F., and Eeles, Rosalind A.

Published
2011
Full Text
View/download PDF

20. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition (vol 118, pg 266, 2018)

Author

Mikropoulos, C., Selkirk, C.G.H., Saya, S., Bancroft, E., Vertosick, E., Dadaev, T., Brendler, C., Page, E., Dias, A., Evans, D.G., Rothwell, J., Maehle, L., Axcrona, K., Richardson, K., Eccles, D., Jensen, T., Osther, P.J., Asperen, C.J. van, Vasen, H., Kiemeney, L.A., Ringelberg, J., Cybulski, C., Wokolorczyk, D., Hart, R., Glover, W., Lam, J., Taylor, L., Salinas, M., Feliubadalo, L., Oldenburg, R., Cremers, R., Verhaegh, G., Zelst-Stams, W.A. van, Oosterwijk, J.C., Cook, J., Rosario, D.J., Buys, S.S., Conner, T., Domchek, S., Powers, J., Ausems, M.G.E.M., Teixeira, M.R., Maia, S., Izatt, L., Schmutzler, R., Rhiem, K., Foulkes, W.D., Boshari, T., Davidson, R., Ruijs, M., Helderman-van den Enden, A.T.J.M., Andrews, L., Walker, L., Snape, K., Henderson, A., Jobson, I., Lindeman, G.J., Liljegren, A., Harris, M., Adank, M.A., Kirk, J., Taylor, A., Susman, R., Chen-Shtoyerman, R., Pachter, N., Spigelman, A., Side, L., Zgajnar, J., Mora, J., Brewer, C., Gadea, N., Brady, A.F., Gallagher, D., Os, T. van, Donaldson, A., Stefansdottir, V., Barwell, J., James, P.A., Murphy, D., Friedman, E., Nicolai, N., Greenhalgh, L., Obeid, E., Murthy, V., Copakova, L., McGrath, J., Teo, S.H., Strom, S., Kast, K., Leongamornlert, D.A., Chamberlain, A., Pope, J., Newlin, A.C., Aaronson, N., Ardern-Jones, A., Bangma, C., Castro, E., Dearnaley, D., Eyfjord, J., Falconer, A., Foster, C.S., Gronberg, H., Hamdy, F.C., Johannsson, O., Khoo, V., Lubinski, J., Grindedal, E.M., McKinley, J., Shackleton, K., Mitra, A.V., Moynihan, C., Rennert, G., Suri, M., Tricker, K., Moss, S., Kote-Jarai, Z., Vickers, A., Lilja, H., Helfand, B.T., Eeles, R.A., and IMPACT Study Collaborators

Published
2018

21. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

Author

Mikropoulos, C., Selkirk, C.G.H., Saya, S., Bancroft, E., Vertosick, E., Dadaev, T., Brendler, C., Page, E., Dias, A., Evans, D.G., Rothwell, J., Maehle, L., Axcrona, K., Richardson, K., Eccles, D., Jensen, T., Osther, P.J., Asperen, C.J. van, Vasen, H., Kiemeney, L.A., Ringelberg, J., Cybulski, C., Wokolorczyk, D., Hart, R., Glover, W., Lam, J., Taylor, L., Salinas, M., Feliubadalo, L., Oldenburg, R., Cremers, R., Verhaegh, G., Zelst-Stams, W.A. van, Oosterwijk, J.C., Cook, J., Rosario, D.J., Buys, S.S., Conner, T., Domchek, S., Powers, J., Ausems, M.G.E.M., Teixeira, M.R., Maia, S., Izatt, L., Schmutzler, R., Rhiem, K., Foulkes, W.D., Boshari, T., Davidson, R., Ruijs, M., Helderman-van den Enden, A.T.J.M., Andrews, L., Walker, L., Snape, K., Henderson, A., Jobson, I., Lindeman, G.J., Liljegren, A., Harris, M., Adank, M.A., Kirk, J., Taylor, A., Susman, R., Chen-Shtoyerman, R., Pachter, N., Spigelman, A., Side, L., Zgajnar, J., Mora, J., Brewer, C., Gadea, N., Brady, A.F., Gallagher, D., Os, T. van, Donaldson, A., Stefansdottir, V., Barwell, J., James, P.A., Murphy, D., Friedman, E., Nicolai, N., Greenhalgh, L., Obeid, E., Murthy, V., Copakova, L., McGrath, J., Teo, S.H., Strom, S., Kast, K., Leongamornlert, D.A., Chamberlain, A., Pope, J., Newlin, A.C., Aaronson, N., Ardern-Jones, A., Bangma, C., Castro, E., Dearnaley, D., Eyfjord, J., Falconer, A., Foster, C.S., Gronberg, H., Hamdy, F.C., Johannsson, O., Khoo, V., Lubinski, J., Grindedal, E.M., McKinley, J., Shackleton, K., Mitra, A.V., Moynihan, C., Rennert, G., Suri, M., Tricker, K., Moss, S., Kote-Jarai, Z., Vickers, A., Lilja, H., Helfand, B.T., Eeles, R.A., and IMPACT Study Collaborators

Subjects
predictive model, prostate cancer, BRCA1, urologic and male genital diseases, genetic predisposition, BRCA2, PSA velocity
Abstract

Background: Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition to PrCa due to BRCA1/2 mutations. This analysis evaluates the utility of PSA and PSAV for identifying PrCa and high-grade disease in this cohort. Methods: PSAV was calculated using logistic regression to determine if PSA or PSAV predicted the result of prostate biopsy (PB) in men with elevated PSA values. Cox regression was used to determine whether PSA or PSAV predicted PSA elevation in men with low PSAs. Interaction terms were included in the models to determine whether BRCA status influenced the predictiveness of PSA or PSAV. Results: 1634 participants had >= 3 PSA readings of whom 174 underwent PB and 45 PrCas diagnosed. In men with PSA >3.0 ng ml(-1), PSAV was not significantly associated with presence of cancer or high-grade disease. PSAV did not add to PSA for predicting time to an elevated PSA. When comparing BRCA1/2 carriers to non-carriers, we found a significant interaction between BRCA status and last PSA before biopsy (P = 0.031) and BRCA2 status and PSAV (P = 0.024). However, PSAV was not predictive of biopsy outcome in BRCA2 carriers. Conclusions: PSA is more strongly predictive of PrCa in BRCA carriers than non-carriers. We did not find evidence that PSAV aids decision-making for BRCA carriers over absolute PSA value alone.

Published
2018

23. Clinical and patient-reported outcomes of SPARE – a randomised feasibility study of selective bladder preservation versus radical cystectomy

Author

Huddart, RA, Birtle, A, Maynard, L, Beresford, Mark, Blazeby, Jane M, Donovan, Jenny L, Kelly, J D, Kirkbanks, T, McLaren, D B, Mead, G, Moynihan, C., Persad, Rajendra A, Scrase, C, Lewis, R, and Hall, A

Subjects
#blcsm, selective bladder preservation, Manchester Cancer Research Centre, Centre for Surgical Research, muscle-invasive bladder cancer, ResearchInstitutes_Networks_Beacons/mcrc, Muscle invasive bladder cancer, #BladderCancer, radical cystectomy, randomised controlled trial, radiotherapy
Abstract

Objectives:To test the feasibility of a randomised trial in muscle invasive bladder cancer (MIBC) and compare outcomes in patients who receive neoadjuvant chemotherapy followed by radical cystectomy or selective bladder preservation, where definitive treatment (cystectomy or radiotherapy) is determined by response to chemotherapy.Patients and methods:SPARE is a multi-centre randomised controlled trial comparing radical cystectomy and selective bladder preservation in patients with MIBC staged T2-3 N0 M0, fit for both treatment strategies and receiving three cycles of neoadjuvant chemotherapy. Patients were randomised between radical cystectomy and selective bladder preservation prior to a cystoscopy after cycle three of neoadjuvant chemotherapy. Patients with ≤T1 residual tumour received a fourth cycle of neoadjuvant chemotherapy in both groups, followed by radical radiotherapy in the selective bladder preservation group and radical cystectomy in in the radical cystectomy group; non-responders in both groups proceeded immediately to radical cystectomy following cycle three. Feasibility study primary endpoints were accrual rate and compliance with assigned treatment strategy. The phase III trial was designed to demonstrate non-inferiority of selective bladder preservation in terms of overall survival in patients whose tumours responded to neoadjuvant chemotherapy. Secondary endpoints included patient reported quality of life, clinician assessed toxicity, loco-regional recurrence free survival and rate of salvage cystectomy after bladder preservation.Results:Trial recruitment was challenging and below the predefined target with 45 patients recruited in 30 months (25 radical cystectomy; 20 selective bladder preservation). Non-compliance with assigned treatment strategy was frequent, 6/25 patients (24%) randomised to radical cystectomy received radiotherapy. Long term bladder preservation rate was 11/15 (73%) in those who received radiotherapy per protocol. Overall survival was not significantly different between groups.Conclusions:Randomising MIBC patients between radical cystectomy and selective bladderpreservation based on response to neoadjuvant chemotherapy was not feasible in the UK health system. Strong clinician and patient preferences for treatments impacted willingness to undergo randomisation and acceptance of treatment allocation. Due to the small number of participants, firm conclusions about disease and toxicity outcomes cannot be drawn.

Published
2017

24. A descriptive survey of cancer helplines in the United Kingdom: Who they are, the services offered, and the accessibility of those services

Author

Leydon, GM, Stuart, B, Danquah, L, Ekberg, K, Brindle, L, Latter, S, Moynihan, C, Salmon, P, Howe, S, Stokoe, E, and Little, P

Subjects
Adult, Counseling, Male, Volunteers, Middle Aged, Health Services Accessibility, United Kingdom, Telephone, Patient Education as Topic, Hotlines, Neoplasms, Surveys and Questionnaires, Humans, Female
Abstract

Background There are more than 1500 UK health helplines in operation, yet we have scant knowledge about the resources in place to support the seeking and delivering of cancer‐related telephone help and support. This research aimed to identify and describe cancer and cancerrelated helpline service provision: the number of helplines available, the variety of services provided, and the accessibility of those services. Methods This study used online national questionnaire survey sent to 95 cancer and cancer-related helplines in the United Kingdom. Results A total of 69 (73%) of 95 surveyed cancer and cancer‐related helplines completed the survey. Most helplines/organizations were registered charities, supported by donations; 73.5% of helplines had national coverage. Most helplines served all age‐groups, ethnic groups, and men and women. Only 13.4% had a number that was free from landlines and most mobile networks, and 56.6% could only be contacted during working hours. More than 50% of helplines reported no provisions for callers with additional needs, and 55% had no clinical staff available to callers. Ongoing support and training for helpline staff was available but variable. Conclusion Although cancer helplines in the United Kingdom offer reasonably broad coverage across the country, there are still potential barriers to accessibility. There are also opportunities to optimize the training of staff/volunteers across the sector. There are further prospects for helplines to enhance services and sustain appropriate and realistic quality standards.

Published
2016

29. Sub-Tg relaxations in heavy metal fluoride glasses

Author

Moynihan, C. T., Opalka, S. M., Mossadegh, R., Crichton, S. N., Bruce, A. J., Araki, H., editor, Ehlers, J., editor, Hepp, K., editor, Kippenhahn, R., editor, Weidenmüller, H. A., editor, Wess, J., editor, Zittartz, J., editor, Beiglböck, W., editor, Dorfmüller, Thomas, editor, and Williams, Graham, editor

Published
1987
Full Text
View/download PDF

35. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study

Author

Bancroft, EK, Page, EC, Castro, E, Lilja, H, Vickers, A, Sjoberg, D, Assel, M, Foster, CS, Mitchell, G, Drew, K, Maehle, L, Axcrona, K, Evans, DG, Bulman, B, Eccles, D, McBride, D, van Asperen, C, Vasen, H, Kiemeney, LA, Ringelberg, J, Cybulski, C, Wokolorczyk, D, Selkirk, C, Hulick, PJ, Bojesen, A, Skytte, AB, Lam, J, Taylor, L, Oldenburg, R, Cremers, R, Verhaegh, G, van Zelst-Stams, WA, Oosterwijk, JC, Blanco, I, Salinas, M, Cook, J, Rosario, DJ, Buys, S, Conner, T, Ausems, MG, Ong, KR, Hoffman, J, Domchek, S, Powers, J, Teixeira, MR, Maia, S, Foulkes, WD, Taherian, N, Ruijs, M, Helderman-van den Enden, AT, Izatt, L, Davidson, R, Adank, MA, Walker, L, Schmutzler, R, Tucker, K, Kirk, J, Hodgson, S, Harris, M, Douglas, F, Lindeman, GJ, Zgajnar, J, Tischkowitz, M, Clowes, VE, Susman, R, Cajal, TRY, Patcher, N, Gadea, N, Spigelman, A, van Os, T, Liljegren, A, Side, L, Brewer, C, Brady, AF, Donaldson, A, Stefansdottir, V, Friedman, E, Chen-Shtoyerman, R, Amor, DJ, Copakova, L, Barwell, J, Giri, VN, Murthy, V, Nicolai, N, Teo, SH, Greenhalgh, L, Strom, S, Henderson, A, McGrath, J, Gallagher, D, Aaronson, N, Ardern-Jones, A, Bangma, C, Dearnaley, D, Costello, P, Eyfjord, J, Rothwell, J, Falconer, A, Gronberg, H, Hamdy, FC, Johannsson, O, Khoo, V, Kote-Jarai, Z, Lubinski, J, Axcrona, U, Melia, J, McKinley, J, Mitra, AV, Moynihan, C, Rennert, G, Suri, M, Wilson, P, Killick, E, Moss, S, Eeles, RA, Taylor, N, Pope, J, Saya, S, Martin, S, Keating, D, Petelin, L, Murphy, M, Doherty, R, Pratt, S, Murphy, D, Cleeve, L, Miller, C, Stapleton, A, Chong, M, Suthers, G, Andrews, L, Duffy, J, Millard, R, Ward, R, Williams, R, Stricker, P, Bowman, M, Patel, M, O'Connell, S, Hunt, C, Smyth, C, Frydenberg, M, Shackleton, K, McGaughran, J, Boon, M, Pachter, N, Townshend, S, Schofield, L, Gleeson, M, Scott, R, Burke, J, Patterson, B, Bacic, S, Swindle, P, Aprikian, A, Bojeson, A, Cruger, D, Osther, P, Gerdes, AM, Rhiem, K, Luedtke-Heckenkamp, K, Ochsendorf, N, Fiddike, K, Sarin, R, Awatagiri, K, Ghonge, S, Kowtal, P, Mulgund, G, Bambury, R, Farrell, M, Gallagher, F, Ben-Yehoshua, SJ, Nissani, R, Appelman, Z, Moriel, E, Radice, P, Valdagni, R, Magnani, T, Meng, TH, Yoon, SY, Thong, MK, Kiemeney, B, Van der Luijt, RB, Moller, P, Brennhovd, B, Medvik, H, Hanslien, E, Peixoto, A, Henrique, R, Oliveira, J, Goncalves, N, Araujo, L, Seixas, M, Joao, PS, Nogueira, P, Krajc, M, Vrecar, A, Capella, G, Fisas, D, Balmana, J, Morote, J, Hjalm-Eriksson, M, Ekdahl, KJ, Carlsson, S, Hanson, H, Shanley, S, Goh, C, Wiggins, J, Kohut, K, Van As, N, Thompson, A, Ogden, C, Borley, N, Woodhouse, C, Kumar, P, Mercer, C, Paterson, J, Taylor, A, Newcombe, B, Halliday, D, Stayner, B, Fleming-Brown, D, Brice, G, Homfray, T, Hammond, C, Potter, A, Renton, C, Searle, A, Hill, K, Goodman, S, Garcia, L, Devlin, G, Everest, S, Nadolski, M, Jobson, I, Paez, E, Tomkins, S, Pichert, G, Jacobs, C, Langman, C, Weston, M, Dorkins, H, Melville, A, Kosicka-Slawinska, M, Cummings, C, Kiesel, V, Bartlett, M, Randhawa, K, Ellery, N, Male, A, Simon, K, Rees, K, Compton, C, Tidey, L, Nevitt, L, Ingram, S, Catto, J, Howson, J, Chapman, C, Cole, T, Heaton, T, Burgess, L, Longmuir, M, Watt, C, Duncan, A, Kockelbergh, R, Sattar, A, Kaemba, B, Sidat, Z, Patel, N, Siguake, K, Birt, A, Poultney, U, Umez-Eronini, N, Mom, J, Roberts, G, Woodward, A, Sutton, V, Cornford, P, Treherne, K, Griffiths, J, Cogley, L, Rubinstein, W, Brendler, C, Helfand, B, McGuire, M, Kaul, K, Shevrin, D, Weissman, S, Newlin, A, Vogel, K, Weiss, S, Goldgar, D, Venne, V, Stephenson, R, Dechet, C, Arun, B, Davis, JW, Yamamura, Y, and Gross, L

Subjects
Prostate cancer, BRCA1, BRCA2, Prostate-specific antigen, Targeted screening
Abstract

Background: Men with germline breast cancer 1, early onset (BRCA1) or breast cancer 2, early onset (BRCA2) gene mutations have a higher risk of developing prostate cancer (PCa) than noncarriers. IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls) is an international consortium of 62 centres in 20 countries evaluating the use of targeted PCa screening in men with BRCA1/2 mutations. Objective: To report the first year's screening results for all men at enrolment in the study. Design, setting and participants: We recruited men aged 40-69 yr with germline BRCA1/2 mutations and a control group of men who have tested negative for a pathogenic BRCA1 or BRCA2 mutation known to be present in their families. All men underwent prostate-specific antigen (PSA) testing at enrolment, and those men with PSA > 3 ng/ml were offered prostate biopsy. Outcome measurements and statistical analysis: PSA levels, PCa incidence, and tumour characteristics were evaluated. The Fisher exact test was used to compare the number of PCa cases among groups and the differences among disease types. Results and limitations: We recruited 2481 men (791 BRCA1 carriers, 531 BRCA1 controls; 731 BRCA2 carriers, 428 BRCA2 controls). A total of 199 men (8%) presented with PSA > 3.0 ng/ml, 162 biopsies were performed, and 59 PCas were diagnosed (18 BRCA1 carriers, 10 BRCA1 controls; 24 BRCA2 carriers, 7 BRCA2 controls); 66% of the tumours were classified as intermediate-or high-risk disease. The positive predictive value (PPV) for biopsy using a PSA threshold of 3.0 ng/ml in BRCA2 mutation carriers was 48%-double the PPV reported in population screening studies. A significant difference in detecting intermediate-or high-risk disease was observed in BRCA2 carriers. Ninety-five percent of the men were white, thus the results cannot be generalised to all ethnic groups. Conclusions: The IMPACT screening network will be useful for targeted PCa screening studies in men with germline genetic risk variants as they are discovered. These preliminary results support the use of targeted PSA screening based on BRCA genotype and show that this screening yields a high proportion of aggressive disease. Patient summary: In this report, we demonstrate that germline genetic markers can be used to identify men at higher risk of prostate cancer. Targeting screening at these men resulted in the identification of tumours that were more likely to require treatment. (C) 2014 European Association of Urology. Published by Elsevier B. V. All rights reserved.

Published
2014

38. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study

Author

Mitra, A.V., Bancroft, E.K., Barbachano, Y., Page, E.C., Foster, C.S., Jameson, C., Mitchell, G., Lindeman, G.J., Stapleton, A., Suthers, G., Evans, D.G., Cruger, D., Blanco, I., Mercer, C., Kirk, J., Maehle, L., Hodgson, S., Walker, L., Izatt, L., Douglas, F., Tucker, K., Dorkins, H., Clowes, V., Male, A., Donaldson, A., Brewer, C., Doherty, R., Bulman, B., Osther, P.J., Salinas, M., Eccles, D., Axcrona, K., Jobson, I., Newcombe, B., Cybulski, C., Rubinstein, W.S., Buys, S., Townshend, S., Friedman, E., Domchek, S., Cajal, T.R.Y., Spigelman, A., Teo, S.H., Nicolai, N., Aaronson, N., Ardern-Jones, A., Bangma, C., Dearnaley, D., Eyfjord, J., Falconer, A., Gronberg, H., Hamdy, F., Johannsson, O., Khoo, V., Kote-Jarai, Z., Lilja, H., Lubinski, J., Melia, J., Moynihan, C., Peock, S., Rennert, G., Schroder, F., Sibley, P., Suri, M., Wilson, P., Bignon, Y.J., Strom, S., Tischkowitz, M., Liljegren, A., Ilencikova, D., Abele, A., Kyriacou, K., Asperen, C. van, Kiemeney, L., Easton, D.F., Eeles, R.A., and IMPACT Study Collaborators

Subjects
prostate cancer BRCA1 BRCA2 PSA genetic predisposition high-risk families jewish men antigen carriers erspc population history trial ng/ml 1st, skin and connective tissue diseases
Abstract

What's known on the subject? and What does the study add? Scientists have found a number of genetic factors that increase prostate cancer risk, including heritable mutations in the genes BRCA1 and BRCA2. These mutations are not common but can have major impact, as a BRCA2 mutation increases risk by up to seven-fold while a BRCA1 mutation is thought to double risk in men under 65. The IMPACT study aims to determine whether targeted screening in men with a known BRCA1 or BRCA2 mutation would lead to earlier diagnosis of prostate cancers. This data from the IMPACT study adds to the increasing evidence that BRCA mutation carriers develop more aggressive disease. Although these are early results, it appears that PSA screening is more accurate at predicting potentially aggressive prostate cancer among men at higher risk of the disease due to a genetic predisposition than general population screening. This study provides support for continued screening in men with genetic mutations. OBJECTIVE To evaluate the role of targeted prostate cancer screening in men with BRCA1 or BRCA2 mutations, an international study, IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls), was established. This is the first multicentre screening study targeted at men with a known genetic predisposition to prostate cancer. A preliminary analysis of the data is reported. PATIENTS AND METHODS Men aged 40-69 years from families with BRCA1 or BRCA2 mutations were offered annual prostate specific antigen (PSA) testing, and those with PSA > 3 ng/mL, were offered a prostate biopsy. Controls were men age-matched (+/- 5 years) who were negative for the familial mutation. RESULTS In total, 300 men were recruited (205 mutation carriers; 89 BRCA1, 116 BRCA2 and 95 controls) over 33 months. At the baseline screen (year 1), 7.0% (21/300) underwent a prostate biopsy. Prostate cancer was diagnosed in ten individuals, a prevalence of 3.3%. The positive predictive value of PSA screening in this cohort was 47 center dot 6% (10/21). One prostate cancer was diagnosed at year 2. Of the 11 prostate cancers diagnosed, nine were in mutation carriers, two in controls, and eight were clinically significant. CONCLUSIONS The present study shows that the positive predictive value of PSA screening in BRCA mutation carriers is high and that screening detects clinically significant prostate cancer. These results support the rationale for continued screening in such men.

Published
2011

39. The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers

Author

Cremers, R, Eeles, RA, Bancroft, EK, Ringelberg, J, Vasen, HF, van Asperen, CJ, Schalken, JA, Verhaegh, GW, Kiemeney, LA, Aaronson, N, Ardem-Jones, A, Bangma, C.H., Castro, E, Dearnaley, D, Eccles, D, Evans, DGR, Eyfjord, J, Falconer, A, Foster, CS (Christopher), Gronberg, H, Hamdy, FC, Johansson, O, Khoo, V, Kote-Jarai, Z, Lija, H, Lubinski, J, Maehle, L, Melia, J, Mikropoulos, C, Mitchell, G, Mitra, AV, Moss, S, Moynihan, C, Page, EC, Rennert, G, Suri, M, Wilson, P, and Urology

Subjects
Oncology, PCA3, Male, medicine.medical_specialty, Urology, Gene mutation, prostate cancer gene 3, Breast Neoplasms, Male, 03 medical and health sciences, Prostate cancer, PSA, 0302 clinical medicine, Breast cancer, SDG 3 - Good Health and Well-being, Prostate, Internal medicine, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Biopsy, medicine, Biomarkers, Tumor, Humans, Early Detection of Cancer, 030304 developmental biology, Aged, Gynecology, marker, 0303 health sciences, medicine.diagnostic_test, business.industry, BRCA mutation, Prostatic Neoplasms, Middle Aged, Prostate-Specific Antigen, medicine.disease, BRCA2, 3. Good health, medicine.anatomical_structure, Prostate cancer screening, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], 030220 oncology & carcinogenesis, Mutation, diagnostic value, business
Abstract

Contains fulltext : 154257.pdf (Publisher’s version ) (Open Access) OBJECTIVE: To evaluate the additive value of the prostate cancer gene 3 (PCA3) urine test to serum prostate-specific antigen (PSA) in prostate cancer (PC) screening among breast cancer, early-onset gene (BRCA) mutation carriers. This study was performed among the Dutch participants of IMPACT, a large international study on the effectiveness of PSA screening among BRCA mutation carriers. MATERIALS AND METHODS: Urinary PCA3 was measured in 191 BRCA1 mutation carriers, 75 BRCA2 mutation carriers, and 308 noncarriers. The physicians and participants were blinded for the results. Serum PSA level>/=3.0ng/ml was used to indicate prostate biopsies. PCA3 was evaluated (1) as an independent indicator for prostate biopsies and (2) as an indicator for prostate biopsies among men with an elevated PSA level. PC detected up to the 2-year screening was used as gold standard as end-of-study biopsies were not performed. RESULTS: Overall, 23 PCs were diagnosed, 20 of which were in men who had an elevated PSA level in the initial screening round. (1) PCA3, successfully determined in 552 participants, was elevated in 188 (cutoff>/=25; 34%) or 134 (cutoff>/=35; 24%) participants, including 2 of the 3 PCs missed by PSA. PCA3 would have added 157 (>/=25; 28%) or 109 (>/=35; 20%) biopsy sessions to screening with PSA only. (2) Elevated PCA3 as a requirement for biopsies in addition to PSA would have saved 37 (cutoff>/=25) or 43 (cutoff>/=35) of the 68 biopsy sessions, and 7 or 11 PCs would have been missed, respectively, including multiple high-risk PCs. So far, PCA3 performed best among BRCA2 mutation carriers, but the numbers are still small. Because PCA3 was not used to indicate prostate biopsies, its true diagnostic value cannot be calculated. CONCLUSIONS: The results do not provide evidence for PCA3 as a useful additional indicator of prostate biopsies in BRCA mutation carriers, as many participants had an elevated PCA3 in the absence of PC. This must be interpreted with caution because PCA3 was not used to indicate biopsies. Many participants diagnosed with PC had low PCA3, making it invalid as a restrictive marker for prostate biopsies in men with elevated PSA levels.

Published
2015
Full Text
View/download PDF

42. Editorial

Author

Moynihan C

Subjects
Cancer Research, Actuarial science, Oncology, business.industry, Non compliance, Medicine, business, Missing data, Quality of Life Research
Published
1998

44. Crossover from ionic hopping to nearly constant loss in the fast ionic conductor Li_(0.18)La_(0.61)TiO_(3)

Author

Rivera Calzada, Alberto Carlos, León Yebra, Carlos, Sanz, J., Santamaría Sánchez-Barriga, Jacobo, Moynihan, C. T., and Ngai, K. L.

Subjects
Electrónica, Electricidad
Abstract

Electrical conductivity measurements of the fast ionic conductor Li_(0.18)La_(0.61)TiO_(3) have been conducted at temperatures ranging from 8 to 300 K and frequencies between 20 Hz and 5 MHz. A detailed analysis of the ac conductivity shows the existence of a crossover between two different regimes. At high temperatures and/or low frequencies correlated ion hopping is responsible for a power-law frequency dependent and thermally activated ac conductivity. On the other hand, at sufficiently low temperatures and/or high frequencies, the ions do not have enough thermal energy or time to hop between neighboring sites, and remain caged. The ac conductivity is then characterized by a linear frequency dependence (i.e., the equivalent of a nearly constant loss) and by a weak exponential temperature dependence of the form exp(T/T_(0)). A crossover between the two regimes is found, which is thermally activated with an activation energy E50.17 eV, significantly lower than that observed for the dc conductivity, E_(δ)50.4 eV. From this result, it is shown that the so-called "augmented Jonscher expression" fails to describe the ac conductivity in the whole frequency and temperature ranges. All these findings suggest that the nearly constant loss originates from electrical loss occurring during the time regime while the ion is still confined in the potential-energy minimum. Further, it is proposed that the loss mechanism involves some type of process where the potential-energy minimum relaxes in time on a time scale much shorter than the ionic hopping time scale. At longer times, as soon as the ion has significant probability of being thermally activated out of the potential well, the nearly constant loss terminates and correlated ion hopping becomes the only contribution to the ac conductivity.

Published
2002

45. 'Dividing the desolation': clients views on the benefits of a cancer counselling service.

Author

Boulton M, Boudioni M, Mossman J, Moynihan C, Leydon G, Ramirez A, Boulton, M, Boudioni, M, Mossman, J, Moynihan, C, Leydon, G, and Ramirez, A

Abstract

This paper describes clients' accounts of the benefits they derived from a short course of cancer counselling provided within a humanist framework. Three hundred and two clients who had attended at least one session of a short course of cancer counselling received an evaluation form, which incorporated both fixed-choice and open-ended questions. One hundred and forty two (47%) clients returned evaluation forms; those who had attended more sessions were significantly more likely to do so. Quantitative data were analysed using SPSS (Statistical Package for the Social Sciences) for Windows and qualitative data using a thematic approach. Almost all clients indicated that they felt they had benefited from counselling. Analysis of the open-ended questions identified nine main benefits of counselling and four key avenues or processes through which clients derived these benefits. Overall, counselling was seen as helping them to work through powerful thoughts and feelings and so to come to terms with cancer and to regain a sense of control in their lives. The benefits of a short course of counselling which clients identified reflect the aims of humanistic counselling which are not well captured by psychiatric assessments or most standard research instruments. In evaluating cancer counselling services, assessments which include these client-defined outcomes may provide a more sensitive way of gauging the value of counselling to a non-clinic population. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

46. Determination of solid mass fraction in partially frozen hydrocarbon fuels

Author

Cotterell, E. M, Mossadegh, R, Bruce, A. J, and Moynihan, C. T

Subjects
Propellants And Fuels
Abstract

Filtration procedures alone are insufficient to determine the amounts of crystalline solid in a partially frozen hydrocarbon distillate fraction. This is due to the nature of the solidification process by which a large amount of liquid becomes entrapped within an interconnected crystalline structure. A technique has been developed to supplement filtration methods with an independent determination of the amount of liquid in the precipitate thereby revealing the actual value of mass percent crystalline solid, %S. A non-crystallizing dye is injected into the fuel and used as a tracer during the filtration. The relative concentrations of the dye in the filtrate and precipitate fractions is subsequently detected by a spectrophotometric comparison. The filtration apparatus was assembled so that the temperature of the sample is recorded immediately above the filter. Also, a second method of calculation has been established which allows significant reduction in test time while retaining acceptable accuracy of results. Data have been obtained for eight different kerosene range hydrocarbon fuels.

Published
1986

47. Crystallization of fluorozirconate glasses

Author

Bansal, Narottam P, Doremus, Robert H, Bruce, A. J, and Moynihan, C. T

Subjects
Nonmetallic Materials
Abstract

The crystallization of a number of glasses of the fluorozirconate family has been studied (using powder X-ray diffraction and DSC) as a function of time and temperature of heating. The main crystalline phases were beta BaZrF6 and beta BaZr2F10. Stable and metastble transformations to the low-temperature alpha phases were also investigated. The size of crystallites in fully devitrified glasses was calculated (from line broadening of the X-ray diffraction peaks) to be about 60 nm.

Published
1984
Full Text
View/download PDF

48. Crystallization of heavy metal fluoride glasses

Author

Bansal, Narottam P, Bruce, Allan J, Doremus, R. H, and Moynihan, C. T

Subjects
Solid-State Physics
Abstract

The kinetics of crystallization of a number of fluorozirconate glasses were studied using isothermal and dynamic differential scanning calorimetry and X-ray diffraction. The addition of the fluorides LiF, NaF, AlF3, LaF3 to a base glass composition of ZrF4-BaF2 reduced the tendency to crystallize, probably by modifying the viscosity-temperature relation. ZrF4-BaF2-LaF3-AlF3-NaF glass was the most stable against devitrification and perhaps is the best composition for optical fibers with low scattering loss. Some glasses first crystallize out into metastable beta-BaZr2F10 and beta-BaZrF6 phases, which transform into the most stable alpha-phases when heated to higher temperatures. The size of the crystallites was estimated to be about 600 A from X-ray diffraction.

Published
1984

Catalog

Books, media, physical & digital resources
See catalog results